Introduction
The Vif protein of human immunodeficiency virus type 1 (HIV-1) is essential for virus replication in cultured human T cells and, in all likelihood, for pathogenic infections in vivo (Gabuzda et al., 1992 von Schwedler et al., 1993; Wieland et al., 1994; Courcoul et al., 1995; Simon and Malim, 1996) . Virus particles expressed in the absence of a functional Vif protein are able to bind to and penetrate susceptible cells but are severely debilitated in their capacity to establish proviruses (Sova and Volsky, 1993; von Schwedler et al., 1993; Simon and Malim, 1996) . Consistent with this, it has been proposed that the defect in vif-deficient infections may be manifested as the postentry instability of viral nucleoprotein complexes (Goncalves et al., 1996; Simon and Malim, 1996) . Significantly, challenges with vif-deficient viruses cannot be rescued back to productivity by the presence of Vif in the target cells (Gabuzda et al., 1992; von Schwedler et al., 1993) . It is believed, therefore, that Vif functions during the late stages of the virus life cycle to confer infectivity on progeny virions. Possibilities for the affected step(s) would therefore include assembly, budding, maturation or some combination thereof.
Analyses of virus particles expressed in the presence or absence of Vif have indicated that Vif's effect, or effects, on the physical properties of virions may be subtle in nature. In particular, even though electron microscopy analyses have indicated that the nucleocapsid cores of vifdeficient virions frequently possess aberrant morphologies (Höglund et al., 1994; Borman et al., 1995; Bouyac et al., 1997) , several groups have reported that Vif does not exert a measurable quantitative or qualitative effect on the virus-encoded components of particles (von Schwedler et al., 1993; Fouchier et al., 1996; Ochsenbauer et al., 1997) . The one known exception to this is the Vif protein itself, which is associated with the viral core and is present at between 10 and 100 copies per virion (Liu et al., 1995; Camaur and Trono, 1996; Fouchier et al., 1996; Karczewski and Strebel, 1996) ; this compares with thẽ 2500 molecules of Gag that are incorporated into each virus particle (Arthur et al., 1992) . However, because the cell-associated levels of Vif in infected T cells are much higher and approach those of the Gag proteins (Camaur and Trono, 1996; Fouchier et al., 1996) , the relevance of virion incorporation for function remains uncertain. Interestingly, in situ analyses of HIV-1-infected cells have indicated that much of the intracellular Vif co-localizes with Gag . Since the HIV-1 Gag and Gag-Pol polyproteins are targeted to the plasma membrane for virus assembly and subsequent budding (Göttlinger et al., 1989; Wang and Barklis, 1993; Yuan et al., 1993; Hunter, 1994; Spearman et al., 1994; Zhou et al., 1994) , this region is presumably a major site of co-localization. Importantly, biochemical fractionations of T cells have also shown that substantial quantities of Vif co-purify with the plasma membrane in the absence of other viral proteins . Taken together, these localization experiments suggest not only that Vif is appropriately positioned to modulate late steps in the viral life cycle but also that targeting to this site is mediated through direct interactions with host cell factors.
A second line of evidence that points towards there being an intimate relationship between Vif function and cellular factors devolves from the observed replication phenotypes of vif-deficient viruses in cultured T cells.
Specifically, whereas primary T lymphocytes isolated from peripheral blood and cell lines such as H9 and HUT78 require the presence of Vif for productive HIV-1 replication (non-permissive cells), other cell lines, for example C8166 and CEM-SS, display no such reliance (permissive cells) (Fisher et al., 1987; Fan and Peden, 1992; Gabuzda et al., 1992; Sakai et al., 1993; Sova and Volsky, 1993; von Schwedler et al., 1993; Borman et al., 1995; Simon et al., 1995) . Accordingly, it is presumed either that permissive cells harbor an activity that substitutes for Vif or, alternatively, that non-permissive cells possess an inhibitory activity that is suppressed by Vif.
Importantly, HIV-1 is not the only retrovirus to carry a vif gene. All lentiviruses of primate hosts (also known as the primate immunodeficiency viruses) and all but one isolated from non-primate hosts-the exception being equine infectious anemia virus (EIAV)-possess vif genes (Oberste and Gonda, 1992; Tomonaga et al., 1992; Gibbs et al., 1994; Reddy et al., 1995; Simon et al., 1995; Harmache et al., 1996) . In contrast, members of the oncovirus and spumavirus subfamilies of retroviruses do not have vif gene equivalents. Previous work has demonstrated that the Vif proteins of HIV-2 and simian immunodeficiency virus from macaques (SIV MAC ) can functionally substitute for HIV-1 Vif in terms of virus replication in human T cells, but that the Vif proteins of three non-primate lentiviruses-visna virus and the feline and bovine immunodeficiency viruses-cannot (Reddy et al., 1995; Simon et al., 1995) . The two most plausible reasons for selectivity with respect to which combinations of cells, viruses and Vif proteins reveal the Vif effect are: first, that a given Vif protein is only functional in cells of a limited number of animal species, or second, that a given Vif only confers infectivity on certain viruses. In molecular terms, the former possibility would suggest that Vif interacts with cellular factors whereas the latter would be more consistent with Vif interacting with viral factors.
To gain insight into the parameters that underlie the specificity of Vif action, we have been focusing on the Vif proteins of the primate lentiviruses. To date, phylogenetic analyses of these viruses have defined five major approximately equidistant lineages (Sharp et al., 1994) ; these are HIV-1/SIV CPZ (CPZ, chimpanzee), HIV-2/ SIV SM /SIV MAC (SM, sooty mangabey), SIV AGM (AGM, African green monkey,) SIV SYK (SYK, Sykes' monkey) and SIV MND (MND, mandrill) . Here, we present evidence that Vif function is determined at the level of the cell rather than the virus. In particular, the HIV-1 Vif protein is able to modulate the infectivity of HIVs, SIVs and a type-C oncoretrovirus, murine leukemia virus (MLV), in human cells whereas the Vif proteins of both SIV AGM and SIV SYK are inactive in human cells irrespective of virus substrate. These results are consistent with a model for Vif function in which virus-expressing cells are modified in a species-specific manner that facilitates the production of infectious retrovirus particles.
Results
The initial objective of these studies was to elucidate the patterns of transcomplementation between primate lentivirus Vif proteins as a step towards determining the mechanism by which this protein family determines virus infectivity. To enable us to make measurements of infectivity in as straightforward and rapid a manner as possible, we have developed the experimental strategy illustrated in Figure 1 . There are two critical components of this system. One, the cells that are employed as virus producers are non-permissive in that vif-deficient viruses expressed by such cells are relatively non-infectious. Specifically, H9 cells and peripheral blood mononuclear cells (PBMCs) can each be used for this purpose as DNAs introduced by transfection display Vif-mediated inductions of infectivity of 10-to 20-fold (Fouchier et al., 1996) . However, H9 cells are preferred over PBMCs for this purpose as DNAs are more readily introduced into these cells by electroporation (data not shown). Two, the T cells that are used as targets of infection harbor the chloramphenicol acetyltransferase (CAT) gene under the transcriptional control of the HIV-1 long terminal repeat (LTR) promoter element (Felber and Pavlakis, 1988; Fouchier et al., 1996; Simon and Malim, 1996) . The extent of infection is therefore measured as the induction of CAT expression since viral Tat proteins expressed by newly formed proviruses (as the result of productive infection) transcriptionally transactivate the resident LTR. It is of note that previous analyses have demonstrated that the HIV-1 LTR is sensitive to transactivation by a variety of HIV and SIV Tat proteins (Sakuragi et al., 1991) . To render the indicator cells susceptible to infection by HIVs and SIVs that utilize different co-receptors for viral entry, the C8166/HIV-CAT cell line (which expresses CD4 and CXCR4) was modified further to express CCR5 and is termed C8166-CCR5/HIV-CAT . A typical experiment therefore consists of transiently transfecting H9 cells with a vifdeficient (or wild-type) provirus expression vector together with a Vif expression vector, normalizing virus stocks according to supernatant reverse transcriptase activity, challenging LTR-CAT indicator cells and determining infection as the accumulation of CAT within 1-2 days.
The Vif proteins of SIV AGM and SIV SYK do not complement vif-deficient HIV-1 or HIV-2 To determine which primate immunodeficiency virus Vif proteins can functionally substitute for the Vif proteins of HIV-1 and HIV-2, a series of virus preparations were Figure  2B ) stocks were harvested and their infectivities determined using C8166/HIV-CAT cells as targets. As expected, the HIV-1 Vif protein efficiently restored infectivity to HIV-1/Δvif (~14-fold induction, Figure 2A ). Also, and consistent with earlier results obtained in spreading infection assays (Reddy et al., 1995; Simon et al., 1995) , the Vif proteins of HIV-2 (~10-fold induction) and SIV MAC (~9-fold induction) both rescued infectivity efficiently. In contrast, no reproducible increases in infectivity over the background values for HIV-1/Δvif were obtained with the Vif proteins of SIVs isolated from African green monkeys (SIV AGM/TAN and SIV AGM/SAB ) or Sykes' monkeys (SIV SYK ). The patterns of complementation of HIV-2/Δvif by the various Vif proteins were essentially the same ( Figure 2B ). Thus, the HIV-1 and cognate HIV-2 Vif proteins conferred infectivity on HIV-2/Δvif (~9-and 7-fold inductions, respectively) whereas the Vifs of SIV AGM/TAN and SIV SYK did not. Importantly, all the pgVif vectors expressed Vif proteins of the expected mass, and the addition of the epitope tag to the carboxy-terminus of each Vif was found not to affect biological activity in terms of the induction of virion infectivity (data not shown).
SIV AGM/TAN Vif regulates SIV AGM/TAN infectivity in African green monkey cells but not in human cells
The finding that the Vif proteins of SIV AGM/TAN , SIV AGM/SAB and SIV SYK did not functionally substitute for HIV-1 Vif but that those of HIV-2 and SIV MAC did was unexpected given that all of these SIV and HIV-2 proteins share between 26 and 29% amino acid sequence identity with the Vif protein of HIV-1. Similarly, the complementation of HIV-2/Δvif by HIV-1 Vif but not by the Vifs of SIV AGM/TAN or SIV SYK was not anticipated as these three proteins each share 29-37% identity with the HIV-2 sequence. We hypothesized that there were four potential (non-mutually exclusive) explanations for these results. One, the Vif proteins of SIV AGM/TAN , SIV AGM/SAB and SIV SYK may not serve the same function in the life cycles of their parental viruses as do the Vifs of HIV-1, HIV-2 and SIV MAC . Two, these particular alleles may be non-functional or inactive. Three, these Vif proteins may not be capable of modulating virus infectivity in cells of human origin. Four, these proteins may not be able to interface with the virion components of HIV-1 or HIV-2 in the manner required for the induction of infectivity.
To address these possibilities, we focused on SIV AGM/TAN and the activity of its Vif protein. To make this experiment as relevant as possible to virus growth in vivo, virus stocks were produced using PBMCs obtained from African green monkeys. We reasoned that the use of these cells for SIV AGM/TAN expression would be akin to the use of human PBMCs (or H9 cells) for HIV-1 Vif analysis, particularly as we are unaware of any immortalized African green monkey lymphoid cell lines. Therefore, by examining SIV AGM/TAN Vif function in PBMCs from both African green monkeys and humans, we anticipated being able to draw conclusions regarding functionality and host cell specificity. Because initial attempts at transfection of African green monkey PBMCs were unsuccessful, an alternative strategy for expressing wild-type and vif-deficient proviruses in PBMCs was developed. Specifically, high titer preparations of wildtype and Δvif viruses that were pseudotyped with the glycoprotein of vesicular stomatitis virus (VSV G) were generated by transfection of 293T cells (a permissive cell line) and used for initial challenges of PBMCs. Since infections of this type are competent with respect to provirus establishment, these cultures served as transient producers of virus particles once the initial inocula had been removed.
Wild-type and vif-deficient SIV AGM/TAN stocks were therefore prepared from PBMCs obtained from African green monkeys and humans; as controls, wild-type and Δvif HIV-1s were generated in parallel from the human PBMCs. All six virus preparations were normalized for reverse transcriptase activity and their respective infectivities examined using C8166-CCR5/HIV-CAT cells as targets ( Figure 3 ). As expected, HIV-1 expressed in the presence of its intact vif gene was markedly more infectious (~90-fold in this experiment) than the Δvif counterpart. It is of note that this increase in infectivity was reminiscent of the~50-fold effect described previously for analogous experiments that employed H9 cells as virus producers (Fouchier et al., 1996; Simon and Malim, 1996) . A similar result was observed when SIV AGM/TAN was produced from cognate African green monkey PBMCs, namely that Vif increased virus infectivity by~16-fold. In sharp contrast, when this same pair of SIV AGM/TAN s was expressed using human PBMCs, the infectivities were not only essentially the same as each other and but were also equivalent to vif-deficient SIV AGM/TAN derived from the African green monkey PBMCs.
A number of important inferences can be made from these observations. First, not only is SIV AGM/TAN Vif a functional protein, but, like the Vifs of HIV-1, HIV-2 and SIV MAC , it is also a potent regulator of virion infectivity. Second, the SIV AGM/TAN Vif protein is inactive in human cells; this is true when either cognate SIV AGM/TAN ( Figure  3 ) or non-cognate HIV-1 or HIV-2 (Figure 2A and B) encoded virus components are present as potential substrates. This latter conclusion implies that if virally encoded factors contribute towards the specificity of Vif action, their interactions with Vif cannot, by themselves, be sufficient to determine Vif function. Accordingly, it seemed possible that the identity (or species) of the host cell, and therefore the ability of certain cellular factors to interact with Vif, could contribute to the functionality of a given Vif protein. 
HIV-1 Vif expressed in human cells confers infectivity on SIV AGM/TAN
To address the possibility that the species of the virusproducing cell, as opposed to the identity of the virus, can determine Vif protein function, we evaluated whether the Vif protein of HIV-1-a virus of humans-is capable of regulating the infectivity of SIV AGM/TAN in human cells. Because we have found that reducing the number of different plasmids that are present in electroporation cocktails results in improved levels of co-expression in transfected H9 cells, we used cell lines that stably expressed Vif, instead of unmodified H9 cells (Figures 1  and 2 ), for the preparation of virus stocks in this experiment; this resulted in the pgVif vectors being eliminated from each transfection.
H9 cell lines that stably expressed the vif gene of HIV-1 or its non-functional Δvif derivative were constructed using retrovirus-mediated gene transfer. Wild-type or vifdeficient provirus expression vectors for HIV-1, HIV-2 and SIV AGM/TAN were transfected into these two cell lines and the infectivity of the resulting virus stocks determined using C8166-CCR5/HIV-CAT cells (Figure 4) . The infectivities of these three sets of viruses segregated into two clear categories. For HIV-1 and HIV-2, the results were entirely as anticipated in that the wild-type viruses (Vif-expressing) were infectious irrespective of cell origin, and the genotypically vif-deficient viruses had relatively low levels of infectivity unless produced from the complementing H9/hVif cells. These results are consistent with those obtained using co-transfections (Figure 2 ).
Interestingly, a very different result was obtained for SIV AGM/TAN (Figure 4 ). For viruses produced from H9/ ΔVif cells, the levels of infectivity were similar whether or not the virus carried an intact vif gene; these findings illustrated, once again, that the Vif protein of SIV AGM/TAN does not function in human cells. The novel and surprising finding was, however, that the infectivities of wild-type and vif-deficient SIV AGM/TAN were significantly increased (~5-fold) when the viruses were produced by cells expressing the HIV-1 Vif protein. Thus, even though the SIV AGM/TAN Vif protein does not regulate the infectivity of its cognate virus in human cells, the Vif protein of the distantly related virus, HIV-1, does. These data not only suggest that interactions between a Vif protein and an infected cell may determine functional outcome in terms of inducing virus infectivity but also imply that these interactions may be governed by species-specific restrictions.
As discussed earlier, Vif is not required for HIV-1 infectivity in certain human T cell lines; such cells have been termed permissive and are exemplified by the CEM-SS line . In terms of supporting the replication of vif-deficient HIV-1, these cells are functionally equivalent to non-permissive cells that contain Vif. To assess whether permissive cells also impart infectivity on SIVs whose Vif proteins are inactive in human cells, the infectivities of SIV AGM/TAN and SIV SYK produced in CEM-SS or H9 cells were determined. For both viruses, it was found that virus stocks produced in CEM-SS cells were~10-fold more infectious than matched samples derived from H9 cells (data not shown). That this was true for both wild-type and Δvif viruses indicated, once again, that the Vif proteins of these SIVs are nonfunctional in human cells. As expected for viruses whose Vif proteins are active in human cells, no such differences were noted for wild-type HIV-1 or HIV-2 expressed in CEM-SS versus H9 cells. It therefore appears that the mechanism(s) by which primate lentiviruses acquire infectivity, either as a result of Vif expression or by virtue of the character of the virus-producing cells, is conserved for viruses of human (HIV-1 and HIV-2) as well as nonhuman (SIV AGM/TAN and SIV SYK ) hosts.
HIV-1 Vif enhances the replication of the oncoretrovirus MLV in human cells
As a further test of the notion that Vif proteins may interact with, and thereby modify, cells in a manner that facilitates the expression of retrovirus particles with increased infectivity, we extended our analysis to the oncoretrovirus MLV. Importantly, and as noted earlier, members of this retrovirus subfamily do not encode equivalents of vif; interestingly, however, it has been demonstrated that it is possible for the Vif protein of HIV-1 to be incorporated into MLV virions (Camaur and Trono, 1996) . As above, we evaluated the effect of the HIV-1 Vif protein on MLV infection in non-permissive (HUT78) as well as permissive (CEM-SS) human T cells; the rationale for this being that a bona fide Vif effect should not be observed in permissive cells. Two different input inocula of amphotropic MLV were therefore used to challenge HUT78 or CEM-SS cells that constitutively expressed either HIV-1 Vif or the corresponding Δvif allele. Virus replication was then monitored over time as the accumulation of reverse transcriptase activity in the culture supernatants ( Figure 5 ). In non-permissive cultures, the expression of HIV-1 Vif either accelerated (higher inoculum) or permitted (lower inoculum) virus replication and dissemination. In contrast, and concordant with the absence of any Vif effect on HIV or SIV infectivity in permissive cells, MLV grew equally well in CEM-SS cells whether Vif was present or not. These novel and unexpected results for MLV are, when taken together with those obtained with SIV AGM/TAN (Figure 4) , consistent with the hypothesis that the interplay between cellular factors and Vif creates an environment that fosters the production of infectious retroviral particles.
Discussion
The critical contribution of the Vif family of proteins to virus infectivity and replication has been established for a variety of primate and non-primate lentiviruses. Although the precise mechanism by which Vif regulates infectivity remains to be defined, the prevailing view is that late steps of the virus life cycle (assembly, maturation and/or budding) are manipulated such that ensuing virions are able to complete reverse transcription and establish proviruses following penetration into susceptible cells (Gabuzda et al., 1992; Sova and Volsky, 1993; von Schwedler et al., 1993; Goncalves et al., 1996; Simon and Malim, 1996) . In an endeavor to understand Vif function in greater detail, we have been investigating the patterns of cross-complementation between the Vif proteins of divergent lentiviruses. It is likely that defining the basis for functional specificity in genetic terms will provide important clues for the design and interpretation of future genetic and biochemical studies.
In these analyses, we have focused our attention on the Vif proteins of four of the five major phylogenetic lineages of primate lentiviruses, namely, HIV-1/SIV CPZ , HIV-2/ SIV SM /SIV MAC , SIV AGM and SIV SYK . Inspection of the amino acid sequences of these proteins is uninformative with respect to predicting cross-complementation capabilities; each pair of Vif proteins among those of the HIV-1 HXB , HIV-2 ROD , SIV AGM/TAN and SIV SYK isolates shares 26-37% sequence identity, yet some are functionally interchangeable whereas others are not. In particular, it was found that the Vif proteins of HIV-1, HIV-2 and SIV MAC (a virus that is closely related to HIV-2) each increases the infectivity of vif-deficient HIV-1 or HIV-2 in human T cells (Figure 2 ). In contrast, no inductions of infectivity for either HIV-1 or HIV-2 were observed with the Vif proteins of SIV AGM or SIV SYK (Figure 2 ). Importantly, it was then found that the Vif proteins of SIV AGM and SIV SYK are also incapable of modulating the infectivity of their parental viruses when human cells are used for virus production ( Figures 3 and 4 and data not shown). To our surprise, however, the infectivity of SIV AGM was significantly increased in human cells by coexpression of the Vif protein of HIV-1 (Figure 4) , a virus that naturally replicates effectively in human cells.
An important aspect of these data that warrants consider- ation is the variations in the magnitude of Vif's effect on infectivity. In particular, the HIV-1 Vif protein increased the infectivity of SIV AGM/TAN by~5-fold (Figure 4) . We speculate that two factors can account for this seemingly low level of induction. First, proviruses that are expressed following transfection exhibit a reduced Vif effect when compared with proviruses expressed as a result of virus infection (Fouchier et al., 1996) ; thus, for HIV-1, transient transfection reveals a 10-to 20-fold effect (Figures 2 and  4) whereas infection results in a 50-to 100-fold effect (Figure 3) . Second, the expression of SIV AGM/TAN Vif enhances the infectivity of its parental virus by only~16-fold in cognate PBMCs, a value well below that seen for HIV-1 in analogous experiments. (Figure 3 ). Accordingly, it is possible that the effects seen in Figure 4 for HIV-1 Vif with SIV AGM/TAN might represent the maximum that could be expected for this transfection-based experiment. The most unexpected, and potentially instructive, observation that was made during the course of these experiments was that HIV-1 Vif significantly enhanced the replication (and by inference the infectivity) of MLV in human T cells ( Figure 5 ). Because this effect, like that of the HIV-1 and HIV-2 Vif proteins on HIV and SIV infection, is mimicked by certain (permissive) cell lines, we favor the idea that the mechanism that underlies Vifmediated increases in infectivity is conserved for all these retroviruses. Important future questions are, therefore, how do Vif proteins exert their influence on virus infectivity, and, what role does the virus-producing cell play in this process? We hypothesize that the restriction of Vif activity to cells of limited host species, exemplified here by SIV AGM Vif being active in African green monkey cells but not in human cells (Figures 3 and 4) , is indicative of interactions between host cell factors and Vif being critical to Vif function. The availability of such species-restricted, yet biologically active, Vif proteins will allow the importance of Vif-host factor binding events (for instance, as might be detected in co-immunoprecipitation or yeast two-hybrid experiments) to be assessed in the context of functional relevance. In addition, the future construction of chimeric vif genes (e.g. using HIV-1 or HIV-2 and SIV AGM ) should make it possible to map the region(s) of Vif that participate in such interactions.
Here, we have argued that specific interactions between Vif proteins and host factors underlie the Vif-induced acquisition of virus infectivity. Importantly, it remains possible that specific interactions between Vif and viral components are also involved. However, one would predict that the structure and/or sequence of such a putative interacting viral component would have to be conserved not only among the primate lentiviruses but also by MLV. It is noteworthy that lentiviruses and MLV assemble their nucleocapsids at the plasma membrane prior to budding (Bolognesi et al., 1978; Gelderblom, 1991; Hunter, 1994) . Because it has been demonstrated previously that a substantial fraction of intracellular HIV-1 Vif is specifically localized to this region of T cells , it will be important to determine whether the infectivities of type-B and type-D retroviruses, such as mouse mammary tumor virus and Mason-Pfizer monkey virus, whose nucleocapsids assemble in the cytoplasm (Fine and Schochetman, 1978; Rhee and Hunter, 1990; Hunter, 1994) , are also sensitive to modulation by Vif. It will also be of interest to examine whether Vif expression can modulate the infectivity of EIAV, the only known lentivirus that lacks a vif gene. The result of such an experiment might allow one to speculate on the possible adaptation of EIAV to growth without Vif.
The discovery that the replication of primate lentiviruses in cells of different species depends on the capacity of Vif to function in those cells may have important implications for the transmission of SIVs to humans and their subsequent evolution into HIVs. Current hypotheses posit that HIV-1 was established in humans on two separate occasions, with SIV CPZ probably serving as the transmitted virus (Sharp et al., 1995) . This compares with HIV-2, which appears to have entered the human population on multiple occasions as SIV SM . Interestingly, no viruses of humans have been identified so far that would appear to be the counterparts of either SIV AGM or SIV SYK . Given that the natural animal hosts of these viruses, in particular African green monkeys (Sharp et al., 1995; Soares et al., 1997) , are distributed abundantly and widely throughout Africa, are usually infected with SIV, and would presumably have frequently come into direct contact with humans, it seems probable that ample opportunity for zoonosis would have occurred. Accordingly, we propose that one factor that may have contributed to the lack of crossspecies transmission of SIV AGM and SIV SYK into humans is the inability of their Vif proteins to function in human cells. Any exposures to humans that might have taken place would be predicted to have been self-limiting as they would have been effectively vif-deficient for the second round of infection. In contrast, human exposures to SIV SM would, at least from the standpoint of Vif function, be expected to result in virus transmission as Vif proteins from this lentivirus lineage are active in human cells.
Coincidentally, a somewhat similar hypothesis was proposed recently following an analysis of the cell cycle arrest capabilities of primate lentivirus Vpr proteins (Stivahtis et al., 1997) . In these and other experiments, it was noted that the Vpr proteins of SIV AGM and SIV SYK are able to induce G2/M arrest in simian (African green monkey) cells but are inactive in human cells (Planelles et al., 1996; Stivahtis et al., 1997) . Thus, two of the accessory proteins of primate immunodeficiency virusesVif and Vpr-are only able to function in cells of a limited number of species. It is feasible, therefore, that both proteins may contribute to the capacity of these viruses to spread between different host species.
Materials and methods

Molecular clones
The wild-type and vif-deficient (Δvif) HIV-1 (pIIIB and pIIIB/Δvif, respectively) as well as the wild-type HIV-2 (pROD10), SIV AGM/TAN (TAN, tantalus monkey), SIV AGM /SAB (SAB, sabaeus monkey) and SIV SYK proviral expression vectors have been described (Hirsch et al., 1993; Jin et al., 1994; Ryan-Graham and Peden, 1995; Simon et al., 1995; Soares et al., 1997) . The vif gene of pROD10 was disrupted by Klenow fragment-mediated fill-in of the XbaI restriction site at position 5624. The SIV-expressing clones were rendered vif-deficient using the Quick Change site-directed mutagenesis kit as directed (Stratagene, La Jolla, CA); in each case, a frameshift mutation was introduced into vif by the insertion of two nucleotides (-GT-), at position 5298 for SIV AGM/TAN and at position 5308 for SIV SYK . The Δvif derivatives of HIV-2, SIV AGM/TAN and SIV SYK therefore express truncated Vif proteins of 46, 27 and 25 amino acids, respectively. The replication-competent amphotropic MLV provirus clone pAM has been described (Miller et al., 1985) .
The Rev-regulated wild-type HIV-1 Vif expression vector pgVif/ HIV-1 was modified by PCR-mediated mutagenesis such that the stop codon of vif was replaced by a BamHI restriction site followed by the T7 epitope tag (Met-Ala-Ser-Met-Thr-Gly-Gly-Gln-GlnMet-Gly-STOP); this vector is termed pgVif:T7/HIV-1. A variant of pgVif/HIV-1 that carried a disrupted (Δvif) vif gene (Simon et al., 1995) , pg/ΔVif, was generated by substitution of the XbaI-SalI fragment with the analogous restriction fragment from pIIIB/Δvif. Analogous vectors harboring the wild-type vif alleles of pROD10, SIV MAC239 , SIV AGM/TAN , SIV AGM/SAB and SIV SYK were constructed by PCR amplification of the relevant gene followed by substitution into pgVif/HIV-1 or pgVif:T7/ HIV-1 as XbaI-SalI or XbaI-BamHI fragments, respectively. The exceptions were pgVif:T7/HIV-2 and pgVif:T7/SIV AGM/SAB , where the substi-tutions were as EcoRI-BamHI and XbaI-BglII fragments. All amplified vif genes were sequenced to confirm integrity.
The retrovirus vectors LN-M/hVif and LN-M/ΔhVif, which express wild-type HIV-1 Vif and its disrupted variant, respectively, have been described (Simon et al., 1995) as have the expression vectors for HIV-1 Rev, pcRev (Malim et al., 1988) , vesicular stomatitis virus envelope, pHIT/G , and MLV gag and gag-pol, pHIT60 (Soneoka et al., 1995) .
Cells and cell lines
The immortalized human cell lines H9, HUT78, CEM-SS and 293T, as well as the modified C8166/HIV-CAT and C8166-CCR5/HIV-CAT lines that each contain the CAT gene under the transcriptional control of the HIV-1 LTR promoter element, have been described (Simon et al., 1995; Simon and Malim, 1996; Fouchier et al., 1997) . Standard retrovirusmediated gene transfer using stocks generated in 293T cells by transfection with one of the LN-M vectors together with pHIT/G and pHIT60 was used to express the wild-type or disrupted HIV-1 vif genes stably in H9, HUT78 or CEM-SS cells . Polyclonal cell populations were selected and maintained in complete RPMI 1640 medium supplemented with 10% fetal bovine serum and 1 mg/ml G418 (Gibco BRL Inc., Gaithersburg, MD).
Human PBMCs were isolated from healthy volunteer donors by venipuncture, purified, stimulated and maintained at~1ϫ10 6 cells/ml in interleukin-2 (IL-2)-containing medium as described . African green monkey PBMCs were obtained and cultured in the same manner using peripheral blood obtained from SIV-negative animals and supplied by the Tulane Regional Primate Center.
Production and quantitation of viruses
For the production of HIVs and SIVs from H9 and CEM-SS cells, or derivative lines, electroporation with provirus vectors, alone or together with Vif expression plasmids or pHIT/G (pseudotyping with VSV G was required for the experiments using SIV SYK proviruses), was performed using 10ϫ10 6 cells and 5-15 μg (total) of DNA. Viruses were harvested at 20 h, filtered through a 0.45 μm filter and the levels of reverse transcriptase activity determined for virus particles pelleted from 0.5 ml of supernatant by centrifugation at 17 000 g for 30 min at 4°C (Goff et al., 1981) ; virus preparations were used for infections immediately after harvest. To express HIV-1 and SIV AGM/TAN from PBMCs, 100 mm monolayers of 293T cells were first transiently co-transfected with the provirus vector and pHIT/G. At 24 h, virus supernatants were collected and used to challenge 10ϫ10 6 PBMCs (1 day after culture in IL-2-containing medium) at high multiplicity. After a further 3 h, input virus was eliminated by three washes in phosphate-buffered saline (PBS), the cells maintained for 3 days in IL-2-containing medium, washed three times with PBS and newly synthesized virions allowed to accumulate for 24 h prior to harvesting and quantitation. Amphotropic MLV was generated by transient transfection of 293T cells with pAM.
Infectivity assays
One-step quantitations of viral infectivity were performed using the C8166/HIV-CAT and C8166-CCR5/HIV-CAT indicator T cell lines. Viruses produced by various means were normalized for each independent experiment, according to reverse transcriptase levels, and used to challenge 0.5ϫ10 6 cells. At 24-48 h post-infection, whole cell lysates were prepared and the levels of CAT activity determined as described Fouchier et al., 1997) .
MLV replication was monitored by supernatant reverse transcriptase activity (Goff et al., 1981) following initial challenge of 2ϫ10 6 cells and subsequent maintenance of the cultures at a density of 0.5-2ϫ10 6 cells/ml.
Western analysis
Total lysates prepared after co-transfection of 293T monolayers with pgVif:T7 vectors in the presence of pcRev were resolved on SDSpolyacrylamide gels and transferred to nitrocellulose. Vif proteins were detected by initial hybridization with a T7-Tag antibody (Novagen, Madison, WI) followed by secondary hybridization with a horseradish peroxidase-conjugated anti-mouse antibody raised in goats. Bound antibody was visualized by enhanced chemiluminescence and autoradiography.
